Patient Experience Survey: Hodgkin Lymphoma with/without Nivolumab (Opdivo) |
Introduction
Thank you for your interest to take part in this online survey of patients & survivors. This survey will be used as part of Lymphoma Canada's submission to the Canadian Drug Agency (www.cda-amc.ca). The Canadian Drug Agency (CDA) assesses drugs for clinical and cost-effectiveness compared to other treatments that are currently available, and makes recommendations to provinces and territories to guide their drug funding decisions.
The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients. The drug that will soon be reviewed by the CDA is for Nivolumab (also referred to as Opdivo). Nivolumab is a PD-1 immune checkpoint inhibitor that works by reactivating T cells to target tumor cells. Nivolumab is being submitted for use in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of patients with previously untreated stage III or IV classical Hodgkin lymphoma.
The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients. The drug that will soon be reviewed by the CDA is for Nivolumab (also referred to as Opdivo). Nivolumab is a PD-1 immune checkpoint inhibitor that works by reactivating T cells to target tumor cells. Nivolumab is being submitted for use in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of patients with previously untreated stage III or IV classical Hodgkin lymphoma.
If you have Hodgkin Lymphoma and have received treatment with Nivolumab (Opdivo), your feedback is extremely important and may help improve access to this new drug for patients in Canada. The greater the response the better our data will be!
YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY.
WE APPRECIATE INPUT FROM ALL HODGKIN LYMPHOMA PATIENTS.
You can still participate if you have not been treated with Nivolumab (Opdivo).
If you have any questions, concerns, or technical difficulties while completing this survey please contact info@lymphoma.ca
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.
If you have any questions, concerns, or technical difficulties while completing this survey please contact info@lymphoma.ca
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.